公开(公告)号：US20240361300A1

公开(公告)日：2024-10-31

申请号：US18660389

申请日：2024-05-10

Applicant: JRD SCIENCE, INC.

Inventor： Christina Rae-Kyung LEE

IPC: G01N33/50 ,  G01N33/68

CPC classification number: G01N33/5023 ,  G01N33/505 ,  G01N33/6896 ,  G01N2333/4703 ,  G01N2333/70578 ,  G01N2333/745 ,  G01N2800/24 ,  G01N2800/28

Abstract: The present invention relates to a biomarker for regulatory T cells.

公开(公告)号：US20240272177A1

公开(公告)日：2024-08-15

申请号：US18561621

申请日：2022-05-16

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Manuel Dietrich ,  Felix Gruenewald ,  Martin Hund ,  Peter Kastner ,  Martin Klammer ,  Ruediger Laubender ,  Heike Wegmeyer ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68 ,  G01N33/536 ,  G01N33/58 ,  G16H50/30

CPC classification number: G01N33/6893 ,  G01N33/536 ,  G01N33/58 ,  G01N33/6854 ,  G16H50/30 ,  G01N2333/4703 ,  G01N2800/361 ,  G01N2800/52

Abstract: The present invention relates to methods of assessing whether a patient has adenomyosis or is at risk of developing adenomyosis, to methods of selecting a patient for therapy of adenomyosis, and methods of monitoring a patient suffering from adenomyosis or being treated for adenomyosis, by determining the amount or concentration of sFRP4 in a sample of the patient, and comparing the determined amount or concentration to a reference.

公开(公告)号：US20240173290A1

公开(公告)日：2024-05-30

申请号：US17790218

申请日：2022-01-12

Applicant: GlaxoSmithKline Intellectual Property (No.3) Limited ,  23andMe, Inc.

Inventor： Janet Mary KUMAR ,  Colin Houston McPHEE ,  Adam Mohamed NAGUIB ,  Lea SAROV-BLAT ,  Claire Yvonne Marie TOWNSEND ,  Paul Bryan WREN ,  Clint Emest YOUNG

IPC: A61K31/353 ,  A61K31/4045 ,  A61K31/573 ,  A61K38/48 ,  A61K45/06 ,  C12N5/0793 ,  C12Q1/6809 ,  G01N33/50 ,  G01N33/68

CPC classification number: A61K31/353 ,  A61K31/4045 ,  A61K31/573 ,  A61K38/4893 ,  A61K45/06 ,  C12N5/0619 ,  C12Q1/6809 ,  G01N33/5058 ,  G01N33/6872 ,  C12Q2600/106 ,  C12Y304/24069 ,  G01N2333/4703 ,  G01N2500/10

Abstract: The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment or prevention of migraine. Combination therapies are also described. In other aspects, the present disclosure provides methods for identifying suitable patients, methods for identifying inhibitors of human TRPM3 and cell lines for use in such methods.

公开(公告)号：US20230348453A1

公开(公告)日：2023-11-02

申请号：US17996514

申请日：2021-04-21

Applicant: iOmx Therapeutics AG

Inventor： Peter SENNHENN ,  Stefan BISSINGER ,  Hannes LOFERER ,  David BANCROFT ,  Tillmann MICHELS ,  Nisit KHANDELWAL

IPC: C07D417/14 ,  G01N33/574 ,  C12Q1/6886 ,  A61P35/00

CPC classification number: C07D417/14 ,  G01N33/57496 ,  C12Q1/6886 ,  A61P35/00 ,  G01N2333/4703 ,  C12Q2600/156

Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder—such as a mixed phenotype acute leukaemia (MPAL)—characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

公开(公告)号：US20230194545A1

公开(公告)日：2023-06-22

申请号：US17995261

申请日：2021-04-02

Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute

Inventor： Sihoun Hahn ,  Christopher Collins ,  Fan Yi ,  Remwilyn Dayuha

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  G01N33/6848 ,  G01N2333/4703 ,  G01N2800/24 ,  G01N2800/222

Abstract: The current disclosure provides antibodies that bind to peptides associated with the primary immunodeficiency disorders (PIDD) Wiskott-Aldrich Syndrome (WAS) and X-linked agammaglobulinemia (XLA). The antibodies can be used in peptide immunoaffinity enrichment coupled to selected reaction monitoring mass spectrometry (immuno-SRM) assays for clinical diagnosis and newborn screening of WAS and XLA, among other uses.

公开(公告)号：US11650206B2

公开(公告)日：2023-05-16

申请号：US16900194

申请日：2020-06-12

Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.

Inventor： Harry Ostrer ,  Johnny C. Loke ,  Alexander Pearlman

IPC: G01N33/574 ,  C12Q1/6886

CPC classification number: G01N33/57496 ,  C12Q1/6886 ,  G01N33/57415 ,  G01N33/57449 ,  G01N33/57484 ,  C12Q2600/156 ,  G01N2333/4703 ,  G01N2333/4748 ,  G01N2333/9108 ,  G01N2440/14 ,  G01N2800/50

Abstract: Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1 complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.

公开(公告)号：US20190204319A1

公开(公告)日：2019-07-04

申请号：US15857870

申请日：2017-12-29

Applicant: Kun-Chun Chiang ,  Chun-Nan Yeh ,  Horng-Heng Juang ,  Ta-Sen Yeh

Inventor： Kun-Chun Chiang ,  Chun-Nan Yeh ,  Horng-Heng Juang ,  Ta-Sen Yeh

IPC: G01N33/574

CPC classification number: G01N33/57415 ,  G01N33/57488 ,  G01N2333/4703

Abstract: A method of screening breast cancer includes collecting serum samples from breast cancer patient; measuring WISP1 level in the serum sample; and comparing the serum WISP1 level of the healthy persons with the WISP1 level in the serum sample of the breast cancer patients. The mean serum WISP1 level is 631.5 pg/ml for healthy persons and the mean serum WISP1 level is 934.5 pg/ml for patients having breast cancer so that WISP1 level of 934.5 pg/ml is configured to be a biomarker in determining whether a subject has high risk of breast cancer occurrence or not.

公开(公告)号：US20180321256A1

公开(公告)日：2018-11-08

申请号：US15773420

申请日：2016-11-07

Applicant: Epizyme, Inc.

Inventor： Christopher PLESCIA

IPC: G01N33/68 ,  A61K31/5377 ,  A61P35/00

CPC classification number: G01N33/6875 ,  A61K31/5377 ,  A61P35/00 ,  G01N33/574 ,  G01N2333/4703 ,  G01N2440/12 ,  G01N2800/52

Abstract: The present disclosure relates to methods of detecting histone epigenetic modifications and compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.

公开(公告)号：US20180246099A1

公开(公告)日：2018-08-30

申请号：US15902614

申请日：2018-02-22

Applicant: TRUSTEES OF BOSTON UNIVERSITY

Inventor： Darrell N. Kotton ,  Finn Hawkins

IPC: G01N33/569 ,  A61K35/42 ,  A61K9/00 ,  C12N5/071

CPC classification number: G01N33/56966 ,  A61K9/007 ,  A61K9/19 ,  A61K35/42 ,  C12N5/0689 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/155 ,  C12N2501/599 ,  C12N2501/999 ,  C12N2506/04 ,  C12N2506/45 ,  G01N2333/4703 ,  G01N2333/70596

Abstract: Provided herein are methods and compositions relating, in part, to the generation and isolation of human lung progenitor cells from pluripotent stem cells.

公开(公告)号：US10054592B2

公开(公告)日：2018-08-21

申请号：US15236953

申请日：2016-08-15

Applicant: Expression Pathology, Inc.

Inventor： David Krizman ,  Todd Hembrough ,  Sheeno Thyparambil

IPC: C12Q1/00 ,  G01N33/574 ,  G01N33/68

CPC classification number: G01N33/57496 ,  G01N33/574 ,  G01N33/6848 ,  G01N2333/4703 ,  G01N2333/62 ,  G01N2333/72 ,  G01N2440/14 ,  G01N2440/38 ,  G01N2560/00 ,  G01N2800/52

Abstract: The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IRS1 protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an IRS1 peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.